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Background: Noonan syndrome is an autosomal, dominantly inherited disease; it is physically characterized by
short stature, short neck, webbed neck, abnormal auricles, high arched palate, and cardiovascular malformation. Its
pathological condition is thought to be due to a gain-of-function mutation in the Ras-mitogen-activated protein
kinase (MAPK) signal transduction pathway. Eyelid abnormalities such as ocular hypertelorism and blepharoptosis
are the most commonly observed eye complications.
Case presentation: We report a case of Noonan syndrome associated with mature cataract that required
operation. A 42-year-old man was diagnosed with Noonan syndrome at the age of 1 year. He underwent an eye
examination after complaining of decreased visual acuity in the right eye and was diagnosed with mature cataract,
which was treated by cataract surgery. There were no intraoperative complications, and the postoperative course
was uneventful. Protein analysis of lens capsule and epithelium at capsulorhexis showed MAPK cascade proteins
such as ERK and p38MAPK were upregulated. An abnormality in the PTPN11 gene was also observed; a potential
mechanism of cataract onset may be that opacity of the lens rapidly progressed due to abnormal activation of
the Ras-MAPK signal transduction pathway.
Conclusion: This case highlights the possible association of cataract formation with MAPK cascade protein
upregulation in Noonan syndrome.
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Noonan syndrome (NS, OMIM 163950) is a common
genetic disorder characterized by congenital heart disease,
short stature, thoracic abnormality, cryptorchidism, men-
tal retardation, and a typical facial appearance, among
other characteristics [1,2]. NS is transmitted as an auto-
somal dominant trait, and is genetically heterogeneous.
Originally, Tartaglia et al. identified missense mutation in
PTPN11, which encode Src homology 2-domain phos-
phatase 2 (SHP-2) in 50% of individuals with NS [3].
Gain-of-function mutations in the PTPN11 gene lead to
activation of the Ras-mitogen-activated protein kinase
(MAPK) signal transduction pathway. Loss-of function or
dominant negative mutations in PTPN11 have been also
documented in individual in NS with multiple lentigines
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reproduction in any medium, provided the or151100)) [4]. So far, heterozygous mutations in nine genes
(PTPN11, KRAS, NRAS, SOS1, RAF1, BRAF, SHOC2,
MEK1, and CBL) in the Ras-MAPK signaling pathway
cause NS or closely related conditions, comprising LS,
Noonan-like syndrome with loose anagen hair (NS/LAH,
OMIM 607721), and the recently documented “CBL muta-
tion associated” syndrome [5,6]. Noonan-like syndromes
comprising Costello syndrome (CS; OMIM 218040), cardi-
ofaciocutaneous syndrome (CFCS, OMIM 115150), neuro-
fibromatosis type 1 (NF1; OMIM 162200), and Legius
syndrome (NFLS, OMIM 611431) are disorders clinically
related to NS and also harbor mutations in HRAS, KRAS,
NF1, BRAF, SPRED1, MEK1, and MEK2 genes [5,6]. These
genes are involved in several developmental processes that
control morphology determination, organogenesis, synap-
tic plasticity, and growth [3-7]. Based on this shared patho-
genetic mechanism and clinical overlap, these diseases
have been grouped into a single family, which has been
termed the Ras-MAPK syndrome, alternatively the RAS-
opathies.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Characteristic facial appearance. Patient presents with
typical appearance such as exophthalmos and abnormal auricles.
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etropia, and cataract have been reported as eye compli-
cations in NS [8]. However, the mechanisms of onset of
cataract in this order are not clear, and only one case
requiring operation has been reported previously [9]. We
reported a case of NS associated with mature cataract that
required operation. We could also prove MAPK activation
and suggested the possible association of MAPK cascade
with cataract formations in this disease.
Materials and methods
Subjects
The Institutional Review Board of the Osaka University
Medical School approved the research protocol, and all
patients provided informed consent. This study was
registered with the approval of Institutional Review Board
of the Osaka University Medical School. In the protein
analysis, the lens capsule and epithelium at capsulorhexis
of the patient with Noonan syndrome or those of senile
cataract patient (as control) were collected during surgery.
Western blot analysis of p38α MAP Kinase and ERK
phosphorylation
After centrifuge, the sediment homogenized in a blender
taken in RIPA buffer (R0278, Sigma-Aldrich, Tokyo,
Japan) supplemented with 1% Protease inhibitor cocktail
(P8340, Sigma-Aldrich) at 4°C. Lysates were placed on
ice for 15 minutes, and centrifuged at 14,000 rpm for
10 minutes at 4°C. The supernatants were collected and
preserved at −70°C. Protein concentrations were deter-
mined by Coomassie Bradford Protein Assay Kit (Catalog
No. 23200, Thermo Fisher Scientific Inc., IL, USA). 13 μg
of the total protein per sample was diluted with Laemmli
Sample Buffer (Catalog No.161-0737, Bio-Rad, CA, USA),
heated at 95°C for 4 min, separated by SDS-PAGE
(Multigel II Mini, Cosmo Bio, Tokyo, Japan), and electro-
blotted onto polyvinylidene fluoride membrane (PVDF,
GE Healthcare, Buckinghamshire, UK). After blocking
with 2.5% skim milk for 1 hour at room temperature, the
membranes were incubated with a p38α MAP Kinase
rabbit monoclonal antibody (1:1000, Catalog No.2371,
Cell Signaling, Danvers, MA, USA), a rabbit polyclonal
anti-phospho-extracellular signal-regulated kinase (ERK)
antibody (1:2000, Catalog No.4370, Cell Signaling), a
rabbit polyclonal anti-ERK to detect total ERK protein
(1:1000, Catalog No.4695, Cell Signaling), or anti-GAPDH
(14C10) (1:2000, Catalog No.2118, Cell Signaling) over
night at 4°C. After washing with 0.1% Tris-buffered saline
(TBS)-Tween, blots were incubated with horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:2500,
Catalog No.7074, Cell Signaling) for 1 h at room tempe-
rature. The blots were then washed three times with 0.1%
TBS-Tween and the signals were visualized by an ECL kit
(GE Healthcare, Buckinghamshire, UK) according to themanufacturer’s protocol. The densities of immunoreactive
bands were measured using Image J for Windows (NIH,
Bethesda, MD, USA).
Case presentation
A 42-year-old man experienced decreased visual acuity in
the right eye before 2 years, but did not seek treatment.
Later, he became aware of severely decreased visual acuity
in the right eye several months ago and visited our hos-
pital. The patient was born at 37 weeks of gestation with a
weight of 2,300 g and had neonatal asphyxia at birth and
had severe jaundice in neonatal period. The patient has a
high arched palate, webbed neck, short neck, ocular hy-
pertelorism, exophthalmos, and dilated cardiomyopathy.
These factors led to a clinical diagnosis of NS at the age of
1 year (Figure 1). Cardiac disease is controlled through the
use of oral drugs. Without receiving growth hormone
treatments, his final body height was 154 cm, which is
below the potential average height of Japanese men. Initial
eye examination suggested that his corrected visual acuity
was 0.06 in the right eye and 0.9 in the left with normal
intraocular pressure. His corneas and irises showed no
abnormalities and no anterior chamber inflammation was
observed. Both eyes showed cataracts, and mature cataract
was observed in the right eye (Figure 2A, B). The patient
had no history of traumatic eye injuries or self-injurious
behavior. The left eye fundus showed no abnormal findings
(Figure 3A, B). Although the right eye fundus could not be
seen, B-mode ultrasonography showed no abnormal find-
ings. No abnormal pupillary light reflexes were observed.
In addition to the mature cataract in the right eye, the cata-
ract in the left eye progressed rapidly during the follow-up
period, leading to decreased visual acuity. Cataract surgery
was indicated for both eyes, and it was performed with no
intraoperative complications (Figure 2C, D). He expe-
rienced no postoperative intraocular pressure elevation,
Figure 2 Slit lamp examination on initial before and after the surgery. Initial slit lamp examination revealed (A) mature cataract in the right
eye (A) and mild cataract in the left eye (B). (A) Mature cataract was observed in the right eye. Slit lamp examination after the cataract surgery in
the right eye (C) and the left eye (D), showing no complication.
Figure 3 Fundus photograph before and after the surgery. (A) Fundus photograph of the right eye, but fundus could not be seen due to
mature cataract. (B) Fundus photograph of the left eye, showing normal appearance. Recent fundus photograph after the cataract surgery in the
right eye (C) and the left eye (D), showing normal appearances.
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Figure 5 Western blot analysis of phosphorylated ERK.
Phosphorylated extracellular signal-regulated kinase (p-ERK1/2)
expression in Western blot. (A) A representative blot. p-ERK expression
in lens lysates from the patient with Noonan syndrome and senile
cataract (control). Western blot analysis revealed that p-ERK expression
increased in lens lysates from the patient with Noonan syndrome. (B)
Semi-quantitative analysis of the band intensity showed an increase in
relative p-ERK expression (values normalized to total ERK expression) in
lens lysates from the patient with Noonan syndrome compared with
that from control (n = 6, *P < 0.001).
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postoperative abnormalities in the right eye fundus
(Figure 3C, D). Genetic analysis revealed a mutation
in the PTPN11 gene. The identified PTPN11 mu-
tations (c.188A > G [p.Tyr63Cys]) encode alterations
located in the N-terminus of SH2 (Src homology 2)
domain, catalytic domain in PTPN11. Protein analysis
also showed that the expression of p38α MAP kinase
was detected in lens lysates from the patient with NS
but, the expression of p38α MAP kinase could not be
detected in patient with senile cataract (control), (Figure 4).
And also, the p-ERK1/2 expressed in a very low level in
lens lysates from the patient with senile cataract (control),
while in the patient with NS, it was significantly increased
(n = 6, P <0.001) (Figure 5). His postoperative corrected
visual acuity was 1.2 in the right eye and 1.0 in the left,
and the postoperative course was uneventful.
Discussion
NS shows physical characteristics similar to those of
Turner syndrome, but occurs in both men and women
with normal karyotypes and is an independent disease
entity from Turner syndrome. Because NS has no explicit
diagnostic criteria, it is diagnosed on the basis of its clinical
manifestations by using a scoring system [10]. van der
Burgt score is usually used for the diagnosis of NS. This
scoring system contains 6 categories with 2 alternatives in
each category [11]. The syndrome is systemically charac-
terized by short stature, short neck, webbed neck, auricular
abnormalities, high arched palate, and cardiovascular mal-
formation, among others. Our patient showed nearly all
systemic abnormalities and was diagnosed with definite NS
during his childhood. Although ocular hypertelorism, epi-
canthus, thick eyelids, palpebral ptosis, and strabismus are
the primary eye symptoms observed in NS [8], there has
been only a report of cataract complications required oper-
ation [9]. Thus, we reported, for the first time, local activa-
tion of MAPK signaling pathway in lens of NS patient.Figure 4 Western blot analysis of p38α MAP Kinase. Western
blot of p38α MAP Kinase in lens capsule and epithelium at
capsulorhexis from the patient with Noonan syndrome and senile
cataract (control). Blot probed with the anti- p38α MAP Kinase anti-
body was detected in lens lysates from the patient with Noonan
syndrome, but not from the patient with senile cataract (control).The MAPK family consists of three subfamilies, such
as extracellular signal-regulated kinase (ERK) 1 and 2,
the c-Jun N-terminal kinase (JNK, also known as the
stress-activated protein kinase), and p38 MAPK. The
classic MAPKs, ERKs, are principally activated in res-
ponse to growth factors, whereas JNK and p38 are acti-
vated by various stresses, including TNF-α treatment,
UV light, x-ray irradiation, heat-shock, and H2O2 treat-
ment [12]. According to the previous reports, transform-
ing growth factor-β (TGF-β) and basic fibroblast growth
factor are crucial factors for lens physiology [13-15].
Binding of these factors to lens cell surface receptors initi-
ate cell signaling pathways that include MAPK/ERK signal
transduction pathway. The RAS/RAF/MEK/ERK pathway
is the classical RAS-MAPK signaling pathway implicated
in growth-factor mediated cell proliferation, differentiation,
and death [16]. In normal state, appropriate expression of
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cataract formation. The Ras-MAPK pathway is reportedly
involved in lens differentiation and maturation [17-19].
We proved MAPK activation in the lens and suggested
the possible association of MAPK signaling cascade with
cataract formation in cataract with NS. Lee NB et al.
reported cataract occurs in 8% of NS [8]. In a study of
congenital heart disease, 3 cases (1.3%) out of 240 had
NS, and congenital cataract was present in six cases
(2.5%) [20], suggesting that the RAS-opathies, a group of
disorders with RAS-MAPK signaling pathway and over-
lapping neuro-cardio-facial-cutaneous phenotypes, play
roles in the possible pathogenesis of this disease. It is
well known that Down syndrome and Turner syndrome
cause cataract as an eye complication. In contrast, NS
shows an overwhelmingly high incidence of corneal and
eyelid abnormalities; although cataract complications are
observed in this disease, the incidence is lower than that
found in Down syndrome [8]. Considering the involve-
ment of MAPK signaling pathway for the cataract for-
mation, genetic analysis revealed a mutation of PTPN11
gene in our patient. The PTPN11 gene is located in the
upstream portion of the Ras-MAPK pathway and is
thought to be involved in cell growth, differentiation,
and senescence [3,21]. The cataract may have been
observed during childhood, but lens opacity may have
increased in severity with aging and accumulation of
metabolic abnormalities, since no abnormalities were
observed in other pathways. It is likely that gain of func-
tion of MAPK signaling pathway in NS patients directly
activated ERK irrespective of TGF-β upregulation and
led to advanced cataract formation.
Conclusions
We report a case of mature cataract complicated by NS
and found the local activation of MAPK signaling
pathway for cataract formation. Although lens opacity
varies in severity, it can progress during the course of
the syndrome. The current case highlights the fact that
periodic observations of the lens opacities are necessary
in patient with NS.
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